These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 2539929

  • 1. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial.
    Bennett WM, Walker RG, Kincaid-Smith P.
    Clin Nephrol; 1989 Mar; 31(3):128-31. PubMed ID: 2539929
    [Abstract] [Full Text] [Related]

  • 2. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
    Parinyasiri U, Ong-Ajyooth L, Parichatikanond P, Ong-Ajyooth S, Liammongkolkul S, Kanyog S.
    J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
    [Abstract] [Full Text] [Related]

  • 3. Effects of eicosapentaenoic acid supplementation on immunoglobulin A nephropathy.
    Uchiyama-Tanaka Y, Mori Y.
    Ther Apher Dial; 2010 Jun; 14(3):303-7. PubMed ID: 20609183
    [Abstract] [Full Text] [Related]

  • 4. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
    Walker RG, Yu SH, Owen JE, Kincaid-Smith P.
    Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
    [Abstract] [Full Text] [Related]

  • 5. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T, Honda K, Nitta K, Yumura W, Nihei H.
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [Abstract] [Full Text] [Related]

  • 6. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
    Donadio JV, Bergstralh EJ, Bibus DM, Grande JP.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
    Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group.
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
    [Abstract] [Full Text] [Related]

  • 8. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.
    Higashihara E, Nutahara K, Horie S, Muto S, Hosoya T, Hanaoka K, Tuchiya K, Kamura K, Takaichi K, Ubara Y, Itomura M, Hamazaki T.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2847-52. PubMed ID: 18372389
    [Abstract] [Full Text] [Related]

  • 9. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Sep; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 10. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
    Uzu T, Harada T, Ko M, Yamato M, Takahara K, Yamauchi A.
    Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
    [Abstract] [Full Text] [Related]

  • 11. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR, Kong NC, Gafor AH, Rahman AF, Zainuddin S, Mustaffa WM, Radzi AM, Shamsul AS.
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [Abstract] [Full Text] [Related]

  • 12. [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group].
    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M.
    Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):503-6. PubMed ID: 9283216
    [Abstract] [Full Text] [Related]

  • 13. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
    Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee EJ, Pwee HS, Lim CH.
    Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
    [Abstract] [Full Text] [Related]

  • 14. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
    Peters HP, van den Brand JA, Wetzels JF.
    Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
    [Abstract] [Full Text] [Related]

  • 15. Can immunosuppressive drugs slow the progression of IgA nephropathy?
    Goumenos D, Ahuja M, Shortland JR, Brown CB.
    Nephrol Dial Transplant; 1995 Feb; 10(7):1173-81. PubMed ID: 7478120
    [Abstract] [Full Text] [Related]

  • 16. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
    Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP.
    J Nephrol; 2001 Feb; 14(4):248-52. PubMed ID: 11506246
    [Abstract] [Full Text] [Related]

  • 17. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW, Fluck RJ, Lambie SH.
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
    Lai KN, Lai FM, Ho CP, Chan KW.
    Clin Nephrol; 1986 Oct; 26(4):174-80. PubMed ID: 3536231
    [Abstract] [Full Text] [Related]

  • 19. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
    Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV, Holub BJ, Southwest Pediatric Nephrology Study Group.
    Clin J Am Soc Nephrol; 2006 May; 1(3):467-74. PubMed ID: 17699247
    [Abstract] [Full Text] [Related]

  • 20. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
    Chábová V, Tesar V, Zabka J, Rychlík I, Merta M, Jirsa M, Stejskalová A, Stejskal J.
    Cas Lek Cesk; 1996 Dec 18; 135(24):803-6. PubMed ID: 9072300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.